Serum BAFF Level Informs Risk of Hypogammaglobulinemia in Patients with Multiple Sclerosis on Ocrelizumab (P5-1.011)
We hypothesized that serum biomarker profile is affected by disease modifying therapy (DMT) and certain biomarkers may inform clinicians on best strategy for DMT management.
Authors
- Michael Sy (ORCID: https://orcid.org/0000-0003-4826-0066)
- Anastasia Chumakova (ORCID: https://orcid.org/0000-0002-5602-578X)
- Victoria Fleming
- Michael Demetriou (ORCID: https://orcid.org/0000-0001-8547-5774)
- Shivani Saxena (ORCID: https://orcid.org/0009-0002-0012-1673)
- Gaby Thai
Institutions
- University of California, Irvine (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000211957
- Primary Topic
- Immunodeficiency and Autoimmune Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00